Key Highlights

  • Arcturus Therapeutics shares closed up 22% at $13.45.
  • The company reported a widened Q2 net loss of $23.8 million as collaboration Revenue declined.
  • A $191.5 million cash position extends the runway through 2028.
  • ARCT-810 clinical data is anticipated September 1, 2026, with a Phase 3 decision for ARCT-032 expected December 1, 2026.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares closed up 22% at $13.45 after the company reported a widened Q2 net loss of $23.8 million as collaboration revenue declined following reduced recognition from CSL Seqirus.

What Happened

Despite the wider loss, a $191.5 million cash position extends the company's runway through 2028, with anticipated September 1, 2026 ARCT-810 clinical data and a December 1, 2026 Phase 3 decision for cystic fibrosis candidate ARCT-032 serving as near-term catalysts.

Market Reaction

Shares rose as investors focused on the extended cash runway and the upcoming clinical catalysts rather than the widened quarterly net loss tied to declining collaboration revenue.

Outlook

The September 1, 2026 ARCT-810 data readout and the December 1, 2026 Phase 3 decision for ARCT-032 represent the next major disclosed milestones for Arcturus Therapeutics.